Lilly commits $50 million to UNICEF child health program over six years
Lilly is giving UNICEF USA $50 million over six years for children's disease prevention in 21 countries, a pledge that does not change U.S. drug prices or coverage.
Eli Lilly and UNICEF USA will work together on a six-year effort to prevent and treat non-communicable diseases in children, backed by a $50 million commitment from the drugmaker, the two organizations said on May 14, 2026 [1]. The program aims to reach more than 30 million young people and caregivers in 21 low- and middle-income countries from 2026 through 2032 [1].
The money goes to UNICEF USA, the U.S. fundraising arm of the United Nations children's agency, and is meant to help UNICEF work with governments to make NCD prevention and care part of routine health services [1]. The conditions named in the announcement are diabetes, congenital heart disease, sickle cell disease and respiratory illness in children and adolescents [1]. The work also covers prevention, care and support for children living with overweight and obesity [1]. UNICEF describes the approach as training and supporting health workers, improving early diagnosis, and expanding long-term care closer to home [1].
Lilly's giving to UNICEF USA has grown. The company committed $14.4 million in 2022 and gave a further $6.5 million in 2024, a total of $20.9 million over roughly five years [2]. The earlier funding started work in Bangladesh, Malawi, Nepal, the Philippines and Zimbabwe, and the 2024 money extended it to India [2]. Lilly and UNICEF say those efforts have reached nearly 16 million children and caregivers [1][2].
"Millions of children are deprived of the building blocks necessary for lifelong health due to Non-communicable disease risk factors established early in life," said Kitty van der Heijden, deputy executive director for partnerships at UNICEF [1]. Patrik Jonsson, executive vice president and president of Lilly International, said the company's work "extends beyond our medicines" [1].
NCDs account for a large share of premature deaths. In 2021, 18 million people died from an NCD before turning 70, and 82 percent of those premature deaths were in low- and middle-income countries, according to World Health Organization figures [2]. Lilly's release cites the same 82 percent figure [1]. Risk factors include unhealthy diets, physical inactivity and tobacco smoke, FiercePharma reported [2].
The announcement lands at a difficult time for UNICEF. Ten months earlier, U.S. lawmakers voted to rescind $142 million in funding for the agency, and UNICEF is working to cut $609 million in costs from 2026 to 2029, including by relocating about 70 percent of headquarters staff in New York and Geneva to cheaper locations [2]. Lilly framed the $50 million gift around its 150th anniversary [1]. Neither organization said how the donation is funded, and neither addressed the prices Lilly charges for its medicines in poorer countries [1][2]. UNICEF said it does not endorse any company brand, product or service [1].
Why it matters for patients
Nothing in the announcement changes what U.S. patients pay for Lilly medicines, what insurers cover, or how these drugs are prescribed. The $50 million goes to health-system work — training, early diagnosis and long-term care — rather than to distributing medicines [1].
The program does overlap with Lilly's commercial focus. FiercePharma describes overweight and obesity as key therapeutic areas for the company, and the UNICEF work includes care for children living with overweight and obesity [2]. How Lilly decides which medicines to discount or donate in low-income countries was not disclosed in either announcement [1][2].
For adults in the U.S. taking or considering a GLP-1 medicine, the practical details — list prices, insurance coverage and access programs — are separate from this pledge and were not part of it [1][2].
What happens next
The commitment runs from 2026 to 2032. Country-by-country targets, a spending schedule and how results will be measured have not been disclosed [1].
Separately, Lilly says it passed its 30x30 goal — quality healthcare for 30 million people a year in resource-limited settings by 2030 — in 2025, five years ahead of schedule [1]. The company says this UNICEF collaboration extends that work [1].
UNICEF's cost-reduction plan covers 2026 through 2029 [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.